Login to Your Account

Can Antisense Trump Oral?

'In a Year, We'll Know': Isis' Kynamro Faces Juxtapid Pill

By Randy Osborne
Staff Writer

Wednesday, January 30, 2013
Timing of the launch, how to identify new patients and the retry for approval in Europe – along with, of course, price – became topics of talk in the aftermath of Kynamro's approval Tuesday by the FDA for homozygous familial hypercholesterolemia (HoFH).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription